ABOLERIS PHARMA is a startup based in France, most recent round Series A, 1 tracked investor.
ABOLERIS PHARMA is a company founded in 2018 headquartered in France. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
AbolerIS Pharma develops potentially best-in-class and first-in-class, curative-intent therapies designed to restore immune tolerance by inducing an immune system reset. The company is advancing a novel class of antibodies that target CD45RC, a key marker on pathogenic Effector T and B cells, to restore immune tolerance by selectively depleting the Effector cells while preserving Regulatory cells and overall immune memory.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.